Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Declines By 73.7%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 1,434 shares, a decrease of 73.7% from the January 15th total of 5,444 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 25,027 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 25,027 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Barinthus Biotherapeutics Stock Up 0.4%

NASDAQ:BRNS opened at $0.71 on Wednesday. The firm’s fifty day simple moving average is $0.72 and its 200 day simple moving average is $1.02. The stock has a market cap of $28.99 million, a P/E ratio of -0.38 and a beta of -0.66. Barinthus Biotherapeutics has a twelve month low of $0.64 and a twelve month high of $2.92.

Analyst Ratings Changes

BRNS has been the topic of several analyst reports. HC Wainwright lifted their target price on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.00.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. boosted its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.